Research review
Resveratrol benefits: what the research does and doesn't show
Human trials of resveratrol supplements are mixed. Some found nothing, a few found changes in specific groups, and none tested the kind of capsule most people buy at its usual dose.
The evidence does not support resveratrol, at any dose, as a supplement with established benefits for healthy adults. Trials are small, doses vary from 75 mg to several grams, several well-run ones found nothing, and the few positive results come from specific groups such as people with diabetes, overweight adults or postmenopausal women. Here is what each trial actually reported.
What the evidence doesn't support
It does not support the idea that resveratrol "does something" for everyone who takes it. The mechanisms that make resveratrol interesting come largely from animal and lab work, and the human trials below did not consistently reproduce them. It does not support a single effective dose, because trials ranged from 75 mg to doses in the grams, and no trial compared them head to head. And it does not let anyone say what a given capsule will do for a given reader. We do not treat resveratrol as a treatment for any condition.
What the trials found
A null result at a low dose. In a randomized, double-blind, placebo-controlled trial, nonobese postmenopausal women with normal glucose tolerance took 75 mg a day for 12 weeks. Blood levels of resveratrol rose, but body composition, resting metabolic rate, blood lipids, inflammatory markers and insulin sensitivity did not change versus placebo, and neither did the molecular targets the researchers measured. The form was not given in the abstract. Certainty: a single, modest trial, but a clear null.
A null result at a high dose. In a randomized, placebo-controlled trial, 24 obese but otherwise healthy men took a high dose of resveratrol (the abstract does not state the milligram figure) for 4 weeks. Insulin sensitivity, the primary outcome, did not differ, and neither did blood pressure, resting energy expenditure, fat content or inflammatory and metabolic biomarkers. The authors wrote that the lack of effect "raises doubt" about resveratrol as a nutritional supplement for metabolic disorders.
A small positive in a small group. In a double-blind crossover trial, 11 obese but otherwise healthy men took 150 mg a day of a branded trans-resveratrol (resVida) for 30 days. The authors reported changes in several measures, among them liver fat, circulating glucose, triglycerides and systolic blood pressure. It is 11 people, men only, a condition-defined group, 30 days, one product; that cannot be extended to anyone else.
A modest memory score, in one group. In a 26-week randomized trial of 46 overweight adults aged 50 to 75, 200 mg a day was followed by better retention of words after 30 minutes versus placebo (p = 0.038), plus changes in hippocampal connectivity, HbA1c and body fat. It was one memory measure in a small sample of older, overweight adults, which says nothing about younger or leaner people.
Postmenopausal women, two research programmes. A 14-week randomized trial in 80 postmenopausal women aged 45 to 85, reported in two papers that appear to describe the same trial, used 75 mg of trans-resveratrol twice a day (150 mg a day). Compared with placebo, verbal memory and overall cognitive scores were better (p = 0.041 and 0.020) and pain and well-being scores improved, with mood not significantly different (PMID 28054939, PMID 28350759). A 24-month crossover trial of the same dose in 125 women, also reported in two papers, found overall cognitive performance 33% better than placebo after 12 months and small gains in spine and hip bone density (PMID 32900519, PMID 32564438). Count these as two trials from one research group, in women who were not otherwise ill, at 150 mg a day of trans-resveratrol, which is not necessarily the dose or form of a capsule a reader may buy. A 2025 meta-analysis of 10 trials in 928 postmenopausal women found lower pain scores and a bone-resorption marker but no effect on cognition, mood, lipids, blood pressure or sleep (PMID 40771919).
Fertility treatment, an association. A retrospective study of embryo-transfer cycles found fewer clinical pregnancies and more miscarriages among 102 women taking 200 mg a day than among 2,958 women who were not (PMID 31160243). It shows association, not cause, and is no guide for or against use, but it is a reason to ask a doctor before taking resveratrol when trying to conceive.
Blood-sugar measures: only in people who already had diabetes. A 2014 meta-analysis pooled 11 randomized trials (388 people). Resveratrol was associated with better glucose control and insulin sensitivity in participants with diabetes, and had no significant effect in participants without it, whatever the dose, trial length or body mass index. The authors called for more high-quality studies.
The big picture. A 2026 umbrella review gathered 45 systematic reviews of randomized trials (129 associations, 68 outcomes). Of 35 statistically significant associations, only four were supported by high-certainty evidence: a 0.8 cm smaller waist circumference, a difference in total cholesterol among overweight adults, and differences in diastolic and systolic blood pressure among people with type 2 diabetes. Others, including glucose metabolism, kidney function, working memory and liver fat, reached moderate certainty. The abstract does not break these down by dose or form, so it cannot tell a reader which dose, if any, produced them.
| Study | Who | Dose and length | Result |
|---|---|---|---|
| Randomized trial | Nonobese postmenopausal women | 75 mg/day, 12 weeks | No change in measured outcomes |
| Randomized trial | 24 obese men | High dose, 4 weeks | No change in measured outcomes |
| Crossover trial | 11 obese men | 150 mg/day, 30 days | Changes in several markers |
| Randomized trial | 46 overweight adults, 50-75 | 200 mg/day, 26 weeks | One memory score better |
| Meta-analysis of 11 trials | 388 people | Varied | Blood-sugar change only in people with diabetes |
Questions people ask
What is resveratrol good for?
The research does not give a clean answer. Where trials found something, it was in specific groups at specific doses; where they tested healthy adults at modest doses, they mostly found nothing.
Is resveratrol good for you?
No trial shows that taking it is good for a healthy person, and no trial shows that it is harmful at modest doses. Safety is covered at resveratrol side effects.
What does resveratrol do for the body?
Studies measured plasma levels, metabolic markers, blood pressure and memory scores, with the mixed results above. In a small 25 mg absorption study, almost none of the dose stayed in the blood as unchanged resveratrol (see what is resveratrol).
Is resveratrol good for skin, or for the liver?
Skin: we did not find a human trial of oral resveratrol on skin that we could verify, so this page makes no statement. Liver: the umbrella review above lists liver fat among moderate-certainty associations, but the abstract does not say in which people or at what dose. Treat that as a lead, not an answer.
Do the benefits depend on the amount, such as 500 mg or 1,000 mg?
The meta-analysis found that, in people without diabetes, dose did not change the (null) result. Beyond that, no trial compared 250, 500 and 1,000 mg directly, so we cannot say what any of those amounts would do. So the doses in the table above are the only numbers we can responsibly give.
What is a "health benefit" claim worth on a label?
Check whether the study behind it used the same dose and form as the product. Most of the studies here did not use a capsule of the kind most people buy.
When to talk to a doctor
Resveratrol is a dietary supplement, not a treatment for diabetes, high blood pressure, high cholesterol, memory problems or any other condition. If you have one of those, or take regular medication, talk to your doctor before adding a supplement, and do not stop or change prescribed treatment because of anything on this page. Medicine interactions are covered at resveratrol and medications.
Sources
- Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance In nonobese postmenopausal women, 75 mg a day for 12 weeks changed none of the measured outcomes versus placebo.
- High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition In 24 obese men, a high dose of resveratrol for 4 weeks changed none of the measured outcomes versus placebo.
- Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans In 11 obese men, 150 mg a day for 30 days was followed by changes in several metabolic markers; it was a small crossover study.
- Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults In 46 overweight adults aged 50 to 75, 200 mg a day for 26 weeks was followed by a modest gain on one word-memory score versus placebo.
- Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials Across 11 trials, resveratrol changed blood-sugar measures in people with diabetes but not in people without it.
- Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials A 2026 review of 45 meta-analyses found high-certainty effects for only four outcomes, three of them in specific groups (overweight adults, people with type 2 diabetes).
- Effects of Resveratrol on Cognitive Performance, Mood and Cerebrovascular Function in Post-Menopausal Women; A 14-Week Randomised Placebo-Controlled Intervention Trial In 80 postmenopausal women, 14 weeks of resveratrol was followed by better verbal memory and overall cognitive scores than placebo.
- Resveratrol supplementation reduces pain experience by postmenopausal women In 80 postmenopausal women, 150 mg a day for 14 weeks was followed by lower pain scores and higher well-being scores than placebo.
- Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study In 125 postmenopausal women, 150 mg a day for 12 months was followed by better overall cognitive scores than placebo.
- Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo-Controlled Trial In postmenopausal women, 75 mg twice a day for 12 months was followed by small increases in bone density at the spine and hip versus placebo.
- Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis Across 10 trials in 928 postmenopausal women, resveratrol was associated with lower pain scores and a lower bone-resorption marker, and nothing else measured.
- Influence of resveratrol supplementation on IVF-embryo transfer cycle outcomes In a retrospective study of IVF cycles, women taking 200 mg a day of resveratrol had lower pregnancy rates and more miscarriages; it shows association, not cause.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.